Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRSPNYSE:NIONYSE:TWLO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRSPCRISPR Therapeutics$41.28-0.6%$37.37$30.04▼$67.88$3.57B1.751.75 million shs1.63 million shsNIONIO$3.62-3.2%$3.77$3.02▼$7.71$7.56B1.6252.77 million shs22.40 million shsTWLOTwilio$115.76-2.1%$103.37$52.51▼$151.95$17.67B1.32.67 million shs2.13 million shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRSPCRISPR Therapeutics-3.31%+9.12%+10.45%-1.12%-33.37%NIONIO-1.19%-0.27%-10.61%-20.84%-15.92%TWLOTwilio-0.73%-1.34%+6.45%+24.96%+105.15%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCRSPCRISPR Therapeutics3.2965 of 5 stars4.32.00.00.02.72.50.6NIONIO1.4383 of 5 stars3.02.00.00.01.10.80.6TWLOTwilio3.9402 of 5 stars2.33.00.03.12.12.51.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRSPCRISPR Therapeutics 2.50Moderate Buy$71.7573.81% UpsideNIONIO 2.08Hold$4.7631.41% UpsideTWLOTwilio 2.68Moderate Buy$125.358.28% UpsideCurrent Analyst Ratings BreakdownLatest NIO, TWLO, and CRSP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/6/2025TWLOTwilioKeyCorpSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$146.006/5/2025TWLOTwilioKeyCorpSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeOverweight$146.006/4/2025NIONIOBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetUnderweight ➝ Underweight$4.00 ➝ $3.006/3/2025NIONIOMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$4.00 ➝ $3.505/21/2025CRSPCRISPR TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$86.00 ➝ $86.005/20/2025CRSPCRISPR TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$81.00 ➝ $81.005/20/2025CRSPCRISPR TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$65.00 ➝ $65.005/16/2025TWLOTwilioNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$125.00 ➝ $125.005/9/2025CRSPCRISPR TherapeuticsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$56.00 ➝ $42.005/8/2025CRSPCRISPR TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$53.00 ➝ $47.005/8/2025TWLOTwilioTigress FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$170.00 ➝ $170.00(Data available from 6/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRSPCRISPR Therapeutics$35M101.86N/AN/A$22.52 per share1.83NIONIO$67.86B0.11N/AN/A$2.11 per share1.72TWLOTwilio$4.58B3.86$0.80 per share144.36$53.49 per share2.16Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRSPCRISPR Therapeutics-$366.25M-$4.52N/AN/AN/A-981.54%-18.46%-15.79%8/4/2025 (Estimated)NIONIO-$2.94B-$1.62N/AN/AN/A-33.41%-113.83%-19.82%N/ATWLOTwilio-$109.40M-$0.21N/A50.114.30-2.45%1.38%1.14%7/30/2025 (Estimated)Latest NIO, TWLO, and CRSP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/3/2025Q1 2025NIONIO-$0.22-$0.45-$0.23-$0.45$12.46 billion$1.66 billion5/6/2025Q1 2025CRSPCRISPR Therapeutics-$1.27-$1.58-$0.31-$1.58N/AN/A5/1/2025Q1 2025TWLOTwilio$0.92$1.14+$0.22$0.12$1.14 billion$1.17 billion3/21/2025Q4 2024NIONIO-$0.33-$0.47-$0.14-$0.47$20.19 billion$2.70 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRSPCRISPR TherapeuticsN/AN/AN/AN/AN/ANIONION/AN/AN/AN/AN/ATWLOTwilioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRSPCRISPR TherapeuticsN/A22.0722.07NIONIO0.981.040.93TWLOTwilio0.125.065.06Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRSPCRISPR Therapeutics69.20%NIONIO48.55%TWLOTwilio84.27%Insider OwnershipCompanyInsider OwnershipCRSPCRISPR Therapeutics4.30%NIONIO1.00%TWLOTwilio0.21%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRSPCRISPR Therapeutics47386.36 million82.26 millionOptionableNIONIO32,8202.09 billion2.07 billionOptionableTWLOTwilio8,160152.67 million146.48 millionOptionableNIO, TWLO, and CRSP HeadlinesRecent News About These CompaniesWedmont Private Capital Acquires New Position in Twilio Inc. (NYSE:TWLO)June 12 at 4:02 AM | marketbeat.comInvesting in Twilio (NYSE:TWLO) a year ago would have delivered you a 107% gainJune 11 at 5:57 PM | finance.yahoo.comTwilio Inc (TWLO) Partners with Orange to Revolutionize RCS Business Messaging in France | TWLO ...June 11 at 4:13 AM | gurufocus.comTwilio and Orange to Bring Secure and Interactive RCS Messaging to Businesses in FranceJune 11 at 3:00 AM | businesswire.comKeyBanc Initiates Coverage Of Twilio (TWLO) with Overweight RatingJune 9 at 2:40 PM | insidermonkey.comTwilio: AI alone won’t cut it – brands must be transparent and tailor engagement to win over Filipino consumers:June 9 at 6:55 AM | manilastandard.netGateway Investment Advisers LLC Reduces Stock Position in Twilio Inc. (NYSE:TWLO)June 9 at 4:59 AM | marketbeat.comTwilio Inc. (NYSE:TWLO) Shares Sold by Rhumbline AdvisersJune 8, 2025 | marketbeat.comGAMMA Investing LLC Has $9.14 Million Stock Position in Twilio Inc. (NYSE:TWLO)June 8, 2025 | marketbeat.comNebius Stock (NBIS) Surges 20% Following a $1B AI Funding RoundJune 8, 2025 | theglobeandmail.comAnalysts Offer Insights on Communication Services Companies: Magnite (MGNI) and Twilio (TWLO)June 8, 2025 | theglobeandmail.comReviewing Twilio (NYSE:TWLO) & CLPS Incorporation (NASDAQ:CLPS)June 8, 2025 | americanbankingnews.comKeyCorp Initiates Coverage on Twilio (NYSE:TWLO)June 8, 2025 | americanbankingnews.comKeyCorp Upgrades Twilio (NYSE:TWLO) to Strong-BuyJune 7, 2025 | marketbeat.comAssessing Twilio: Insights From 20 Financial AnalystsJune 6, 2025 | benzinga.comKeybanc Initiates Coverage of Twilio (TWLO) with Overweight RecommendationJune 6, 2025 | msn.comHere is What to Know Beyond Why Twilio Inc. (TWLO) is a Trending StockJune 6, 2025 | zacks.comTwilio (NYSE:TWLO) Now Covered by Analysts at KeyCorpJune 6, 2025 | marketbeat.comOxinas Partners Wealth Management LLC Invests $237,000 in Twilio Inc. (NYSE:TWLO)June 6, 2025 | marketbeat.comWealth Enhancement Advisory Services LLC Purchases 4,595 Shares of Twilio Inc. (NYSE:TWLO)June 6, 2025 | marketbeat.comInsider Selling: Twilio Inc. (NYSE:TWLO) Director Sells 4,100 Shares of StockJune 5, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy Goldman Sachs Suddenly Boosted These 3 Trucking StocksBy Gabriel Osorio-Mazilli | June 9, 2025View Why Goldman Sachs Suddenly Boosted These 3 Trucking StocksMicrosoft Could Rally as EU Antitrust Case Nears ResolutionBy Chris Markoch | May 21, 2025View Microsoft Could Rally as EU Antitrust Case Nears Resolution3 Quality Stocks Trading Near 52-Week LowsBy Gabriel Osorio-Mazilli | May 30, 2025View 3 Quality Stocks Trading Near 52-Week LowsIs NIO Stock Set for a Comeback? Fundamentals Say YesBy Gabriel Osorio-Mazilli | May 19, 2025View Is NIO Stock Set for a Comeback? Fundamentals Say YesX: 1 Reason to Bet on U.S. Steel, and 1 Reason to Hold BackBy Sam Quirke | June 7, 2025View X: 1 Reason to Bet on U.S. Steel, and 1 Reason to Hold BackNIO, TWLO, and CRSP Company DescriptionsCRISPR Therapeutics NASDAQ:CRSP$41.28 -0.24 (-0.58%) As of 04:00 PM EasternCRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.NIO NYSE:NIO$3.62 -0.12 (-3.21%) As of 03:59 PM EasternNIO Inc. designs, manufactures, and sells electric vehicles in the People's Republic of China. The company is also involved in the manufacture of e-powertrain, battery packs, and components; and racing management, technology development, and sales and after-sales management activities. In addition, it offers power solutions for battery charging needs; and other value-added services. The company was formerly known as NextEV Inc. and changed its name to NIO Inc. in July 2017. NIO Inc. was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.Twilio NYSE:TWLO$115.76 -2.43 (-2.06%) As of 03:59 PM EasternTwilio Inc., together with its subsidiaries, provides customer engagement platform solutions in the United States and internationally. It operates through two segments, Twilio Communications and Twilio Segment. The company provides various application programming interfaces and software solutions for communications between customers and end users, including messaging, voice, email, flex, marketing campaigns, and user identity and authentication. It also offers software products to build direct, personalized relationships with their end users, such as segment, a platform that provides tools for first-party data by unifying real-time information collected; and engage, an automation platform for the delivery of omnichannel campaigns. Twilio Inc. was incorporated in 2008 and is headquartered in San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Oracle’s Cloud Boom Is Just Getting Started Netflix Sets New Highs—Price Targets Keep Climbing IonQ’s $1B Acquisition and Drug Discovery Leap With NVIDIA Alibaba’s Dip Is a Gift—Here’s the Price That Matters Betting on Disruption: Is Lemonade the Future of Insurance? Starbucks Stock: Culture Fix May Be Key to Long-Term Growth GameStop Turns a Profit, But Core Business Keeps Shrinking Why a Trump-Musk Feud Could Mean Big Wins for AST SpaceMobile Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
